Farzana Pashankar
Research & Publications
Biography
News
Research Summary
My areas of interest include Sickle cell disease and Solid Tumors especially germ cell tumors and rare cancers. In sickle cell disease, my research has focused on a variety of areas including identifying the prevalence and risk factors of various complications, management of these complications and quality improvement projects to decrease the burden of disease and improve quality of life.
In oncology, my research activities have focused on collaborative studies through the Children's Oncology Group ( COG) in germ cell tumors and rare tumors. I serve on the steering committees for Germ Gell Tumors and Rare Tumors at COG. I am a member of the Malignant Germ Cell Tumor International Collaborative. Through this collaborative, we have merged 25 years of clinical trial data from US and UK pediatric and adult germ cell clinical trials. This has helped us redefine risk stratification and conduct several analyses. I took leadership of analyzing the data on ovarian immature teratomas. Ovarian immature teratomas are a rare malignancy. There is significant difference in treatment approach between the adult and pediatric groups. In pediatrics, patients are primarily treated with surgery alone, whereas adults receive chemotherapy for all ovarian IT, except Stage I, grade 1 patientsI analyzed the pediatric and adult clinical trial data, and found that grade was the most important risk factor for relapse. More importantly, I found that despite a wide difference in treatment approaches, between adults and pediatrics, the outcomes were similar, bringing up the question of the necessity of adjuvant chemotherapy for ovarian IT.
Specialized Terms: Clinical trials in Pediatric Oncology; Sickle cell anemia
Extensive Research Description
1. Sickle Cell Disease
My research has focused on a variety of areas including identifying the prevalence and risk factors of various complications, management of these complications and quality improvement projects to decrease the burden of disease and improve quality of life.
In the 1990’s, a landmark study from the NIH reported that pulmonary hypertension occurred in a third of adults and was associated with increased mortality. There was limited data in children. I thus designed the first prospective screening study and identified that elevated pulmonary artery pressures (PAP) occur in 30% of children, and is associated with hypoxia, hemolysis and a high platelet count. This was published in Pediatrics and has been widely quoted. Although elevated PAP occurred in children, there was no data on the long-term outcome and possible reversibility of this complication. I conducted a single institution pilot study to determine if treatment with Hydroxyurea, an antihemolytic agent could reverse elevated PAP in children. This study showed that elevated PAP was reversible with hydroxyurea and was published in British Journal of Hematology. Due to the exciting results from our single center pilot, we secured CTSA funding and conducted a multicenter study. This study showed that hydroxyurea improved oxygenation in SCD and had a trend in decreasing PAP.
Working with a medical student, we studied the association of PAP with other complications and found that elevated PAP was associated with early signs of nephropathy. This was the first study describing this association.
Over the years I have collaborated with colleagues at Yale and through the New York Connecticut Consortium and New England Pediatric Sickle Cell consortium to study other complications such as retinopathy, AVN, obesity and determine genetic determinants of hydroxyurea response and look at barriers to hydroxyurea use.
Recently I have focused on quality improvement projects to improve pain management at home and decrease ED visits and hospitalizations. This has been very successful in reducing hospitalizations and improving the quality of life for these families. This work was published and has been adopted by many institutions.
Current Studies and Future Direction:
1. Understanding and Addressing the Social Determinants of Health for Families of Children with Sickle Cell Anemia within Pediatric Hematology
2. Rare Tumors
I was the chair of the Infrequent Tumor Subcommittee at COG till 2020. We developed and published guidelines for several rare tumors and have recently completed two international clinical trials, on adrenocortical carcinoma and nasoparyngeal carcinoma.
3. Germ Cell Tumors
In germ cell tumors, my research has focused on redefining management of immature teratomas (IT) and clinical trial development. The management of ovarian IT is controversial. In children, ovarian IT is treated with surgery alone, whereas adults treat all patients with chemotherapy except those with Stage I, grade 1 tumors. I analyzed pediatric and adult clinical trial data from the MaGIC database and found that grade was the most important risk factor for relapse. In patients with grade 3 tumors, the outcome was similar between the pediatric and adult cohort despite a marked difference in treatment, questioning the role of chemotherapy. Since that initial analyses, I have published other reports showing chemo unresponsiveness of ovarian IT. We have also diligently worked with the adult gynecologic oncology community to move away from using chemotherapy postoperatively in ovarian IT.
Our efforts have been somewhat successful and while designing the current open trial AGCT1531 in conjunction with Gynecology Oncology Group, they agreed to observation alone not only for stage I, grade 1 tumors but also for Stage I, grade 2 and 3 tumors. This is a major change and has the potential to spare chemotherapy to many adult women if the trial proves our hypothesis. We are currently working on an amendment to expand surveillance alone to all patients with ovarian IT, irrespective of stage and I am also organizing a pathology consensus conference to standardize grading of IT.
Another area that I have been actively involved in is clinical trial development at Children’s Oncology Group (COG). Currently we have two clinical trials open – I am the Vice Chair on an international trial for low and intermediate risk germ cell tumors and am the Chair for all US sites for an international trial for poor risk germ cell tumors run by Australia New Zealand Urogenital group, that is open in the US through National Clinical Trials Network.
At Yale, I direct the solid tumor program, and have been actively working to bring innovative industry sponsored trials in addition to trial through COG to broaden our trial portfolio.
Coauthors
Research Interests
Anemia, Sickle Cell; Echocardiography; Hematology; Hypertension, Pulmonary; Medical Oncology; Pediatrics
Selected Publications
- Loss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology GroupPuthenpura V, Ji L, Xu X, Roth M, Freyer D, Frazier A, Marks A, Pashankar F. Loss to follow‐up of minorities, adolescents, and young adults on clinical trials: A report from the Children's Oncology Group Cancer 2023, 129: 1547-1556. PMID: 36813754, DOI: 10.1002/cncr.34701.
- P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs).Zebic D, Stockler M, Martin A, Pashankar F, Tran B, Mazhar D, Huddart R, Wheater M, Walpole E, Dunwoodie E, Feldman D, Birtle A, Stevanovic A, Wyld D, Hanning F, Grimison P. P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs). Journal Of Clinical Oncology 2023, 41: tps431-tps431. DOI: 10.1200/jco.2023.41.6_suppl.tps431.
- Sense of mastery and attitude towards illness: Examining longitudinal benefits of a medical specialty camp for youth with sickle cell diseaseGillard A, Gagnon R, Pashankar F, Balsamo L, Grafft N, Miranda J, Boruchov D, Neri C, Sprinz P, Longyear C. Sense of mastery and attitude towards illness: Examining longitudinal benefits of a medical specialty camp for youth with sickle cell disease Clinical Child Psychology And Psychiatry 2022, 28: 1012-1023. PMID: 36503316, DOI: 10.1177/13591045221145425.
- Metastatic and multiply relapsed SDH‐deficient GIST and paraganglioma displays clinical response to combined poly ADP‐ribose polymerase inhibition and temozolomideSingh C, Bindra RS, Glazer PM, Vasquez JC, Pashankar F. Metastatic and multiply relapsed SDH‐deficient GIST and paraganglioma displays clinical response to combined poly ADP‐ribose polymerase inhibition and temozolomide Pediatric Blood & Cancer 2022, 70: e30020. PMID: 36151992, DOI: 10.1002/pbc.30020.
- Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conferencePashankar F, Hanley K, Lockley M, Stoneham S, Nucci MR, Reyes-Múgica M, Elishaev E, Vang R, Veneris J, Rytting H, Olson T, Hazard K, Covens A, Arora R, Billmire D, Al-Ibraheemi A, Ulbright TM, Frazier L, Hirsch MS. Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference European Journal Of Cancer 2022, 173: 59-70. PMID: 35863107, DOI: 10.1016/j.ejca.2022.06.006.
- Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology groupDicken B, Billmire D, Rich B, Hazard F, Nuño M, Krailo M, Fallahazad N, Pashankar F, Shaikh F, Frazier A. Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group Gynecologic Oncology 2022, 166: 476-480. PMID: 35750503, PMCID: PMC9514449, DOI: 10.1016/j.ygyno.2022.06.013.
- The United StatesPashankar F, Rodriguez-Galindo C. The United States 2022, 55-58. DOI: 10.1007/978-3-030-92071-5_7.
- Prevalence and risk factors of cognitive impairment in children with sickle cell disease in EgyptYoussry I, ElGhamrawy M, Seif H, Balsamo L, Pashankar F, Mahrous M, Salama N. Prevalence and risk factors of cognitive impairment in children with sickle cell disease in Egypt International Journal Of Hematology 2021, 115: 399-405. PMID: 34792734, DOI: 10.1007/s12185-021-03260-1.
- Re: ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis’Lockley M, Stoneham S, Shamash J, Pashankar F, Frazier L. Re: ‘Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis’ European Journal Of Cancer 2021, 152: 255-256. PMID: 34099362, DOI: 10.1016/j.ejca.2021.05.001.
- Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 ProtocolRodriguez-Galindo C, Krailo MD, Pinto EM, Pashankar F, Weldon CB, Huang L, Caran EM, Hicks J, McCarville MB, Malkin D, Wasserman JD, de Oliveira Filho AG, LaQuaglia MP, Ward DA, Zambetti G, Mastellaro MJ, Pappo AS, Ribeiro RC. Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol Journal Of Clinical Oncology 2021, 39: 2463-2473. PMID: 33822640, PMCID: PMC8462560, DOI: 10.1200/jco.20.02871.
- Bone marrow transplant using fludarabine‐based reduced intensity conditioning regimen with in vivo T cell depletion in patients with Fanconi anemiaGorfinkel L, Demsky C, Pashankar F, Kupfer G, Shah NC. Bone marrow transplant using fludarabine‐based reduced intensity conditioning regimen with in vivo T cell depletion in patients with Fanconi anemia Pediatric Transplantation 2021, 25: e14009. PMID: 33755277, DOI: 10.1111/petr.14009.
- Racial/ethnic, socioeconomic, and geographic survival disparities in adolescents and young adults with primary central nervous system tumorsPuthenpura V, Canavan ME, Poynter JN, Roth M, Pashankar FD, Jones BA, Marks AM. Racial/ethnic, socioeconomic, and geographic survival disparities in adolescents and young adults with primary central nervous system tumors Pediatric Blood & Cancer 2021, 68: e28970. PMID: 33704901, PMCID: PMC8221084, DOI: 10.1002/pbc.28970.
- P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs).Subramaniam S, Toner G, Stockler M, Martin A, Pashankar F, Tran B, Jeffery M, Mazhar D, Huddart R, Walpole E, Stevanovic A, Wyld D, Hanning F, Wheater M, Balagtas J, Troon S, Birtle A, White J, Grimison P. P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs). Journal Of Clinical Oncology 2021, 39: tps390-tps390. DOI: 10.1200/jco.2021.39.6_suppl.tps390.
- Pulmonary Metastasis of Low-risk Perinatal Neuroblastoma After Resection: Implications for SurveillanceUllrich SJ, Worhunsky D, Rodwin R, Pashankar F, Christison-Lagay E, Ozgediz D. Pulmonary Metastasis of Low-risk Perinatal Neuroblastoma After Resection: Implications for Surveillance Journal Of Pediatric Hematology/Oncology 2021, 43: e184-e186. PMID: 31815890, DOI: 10.1097/mph.0000000000001693.
- Emotion regulation, pain interference and affective symptoms in children and adolescents with sickle cell diseaseMiller M, Balsamo L, Pashankar F, Bailey CS. Emotion regulation, pain interference and affective symptoms in children and adolescents with sickle cell disease Journal Of Affective Disorders 2020, 282: 829-835. PMID: 33601724, DOI: 10.1016/j.jad.2020.12.068.
- Imaging Appearance of Nongerminoma Pediatric Ovarian Germ Cell Tumors Does Not Discriminate Benign from Malignant HistologyBillmire D, Dicken B, Rescorla F, Ross J, Piao J, Huang L, Krailo M, Pashankar F, Frazier L, Group C. Imaging Appearance of Nongerminoma Pediatric Ovarian Germ Cell Tumors Does Not Discriminate Benign from Malignant Histology Journal Of Pediatric And Adolescent Gynecology 2020, 34: 383-386. PMID: 33316416, PMCID: PMC8096645, DOI: 10.1016/j.jpag.2020.11.014.
- Patterns of medication use at end of life by pediatric inpatients with cancerProzora S, Shabanova V, Ananth P, Pashankar F, Kupfer GM, Massaro SA, Davidoff AJ. Patterns of medication use at end of life by pediatric inpatients with cancer Pediatric Blood & Cancer 2020, 68: e28837. PMID: 33306281, DOI: 10.1002/pbc.28837.
- Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International ConsortiumShaikh F, Stark D, Fonseca A, Dang H, Xia C, Krailo M, Pashankar F, Rodriguez‐Galindo C, Olson TA, Nicholson JC, Murray MJ, Amatruda JF, Billmire D, Stoneham S, Frazier AL. Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium Cancer 2020, 127: 193-202. PMID: 33079404, DOI: 10.1002/cncr.33273.
- Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcomaHegde M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, Byrd TT, Hicks J, Xu ML, Gerken C, Kalra M, Robertson C, Zhang H, Shree A, Mehta B, Dakhova O, Salsman VS, Grilley B, Gee A, Dotti G, Heslop HE, Brenner MK, Wels WS, Gottschalk S, Ahmed N. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma Nature Communications 2020, 11: 3549. PMID: 32669548, PMCID: PMC7363864, DOI: 10.1038/s41467-020-17175-8.
- Re: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practicePashankar F, Frazier AL. Re: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice European Journal Of Cancer 2020, 130: 265-266. PMID: 32178968, DOI: 10.1016/j.ejca.2020.01.022.
- P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).Subramaniam S, Toner G, Stockler M, Martin A, Pashankar F, Frazier A, Mazhar D, Ford K, Walpole E, Stevanovic A, Wyld D, Troon S, Hanning F, Birtle A, Wheater M, Huddart R, White J, Spunt S, Grimison P. P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs). Journal Of Clinical Oncology 2020, 38: tps425-tps425. DOI: 10.1200/jco.2020.38.6_suppl.tps425.
- 3.22 EMOTION REGULATION IN PEDIATRIC SICKLE CELL PATIENTS: ASSOCIATIONS WITH SYMPTOMS OF DEPRESSION, ANXIETY, AND PAIN INTERFERENCEMiller M, Bailey C, Pashankar F, Balsamo L. 3.22 EMOTION REGULATION IN PEDIATRIC SICKLE CELL PATIENTS: ASSOCIATIONS WITH SYMPTOMS OF DEPRESSION, ANXIETY, AND PAIN INTERFERENCE Journal Of The American Academy Of Child & Adolescent Psychiatry 2019, 58: s202. DOI: 10.1016/j.jaac.2019.08.185.
- Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study.Rodriguez-Galindo C, Krailo MD, Krasin MJ, Huang L, McCarville MB, Hicks J, Pashankar F, Pappo AS. Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study. Journal Of Clinical Oncology 2019, 37: 3369-3376. PMID: 31553639, PMCID: PMC6920031, DOI: 10.1200/jco.19.01276.
- GCT-40 Alpha-fetoprotein (AFP) as a predictor of outcome for children with germ cell tumours: A report from the Malignant Germ Cell International Consortium (MaGIC)O’Neill A, Xia C, Krailo M, Shaikh F, Pashankar F, Billmire D, Olson T, Amatruda J, Villaluna D, Huang L, Malogolowkin M, Rodriguez-Galindo C, Frazier A. GCT-40 Alpha-fetoprotein (AFP) as a predictor of outcome for children with germ cell tumours: A report from the Malignant Germ Cell International Consortium (MaGIC) European Urology Open Science 2019, 18: 19. DOI: 10.1016/s1569-9056(19)32507-2.
- GCT-42 Validation of the MaGIC paediatric germ cell tumour risk stratificationFrazier A, Faure-Conter C, Fresneau B, Lopes L, Pashankar F, Shaikh F, O’Neill A, Amatruda J, Krailo M, Klosterkemper L, Piao J, Dang H, Xia C, Stoneham S, Murray M, Nicholson J. GCT-42 Validation of the MaGIC paediatric germ cell tumour risk stratification European Urology Open Science 2019, 18: 20. DOI: 10.1016/s1569-9056(19)32509-6.
- GCT-03 The Malignant Germ Cell International Consortium (MaGIC)Frazier A, Krailo M, Amatruda J, Murray M, Lopes L, Faure-Conter C, Stoneham S, Pashankar F, Shaikh F, Chinnaswamy G, Xie Y, Gershenson D, Covens A, Olson T, Klosterkemper L, Nicholson J, investigators O. GCT-03 The Malignant Germ Cell International Consortium (MaGIC) European Urology Open Science 2019, 18: 6. DOI: 10.1016/s1569-9056(19)32470-4.
- GCT-10 Outcomes of adolescent males with extracranial metastatic germ cell tumours compared with children and young adults: A report from the Malignant Germ Cell Tumour International Consortium (MaGIC) groupShaikh F, Stark D, Dang H, Xia C, Krailo M, Stenning S, Pashankar F, Rodriguez-Galindo C, Olson T, Depani S, Stoneham S, Nicholson J, Murray M, Amatruda J, Billmire D, Fonseca A, Frazier A. GCT-10 Outcomes of adolescent males with extracranial metastatic germ cell tumours compared with children and young adults: A report from the Malignant Germ Cell Tumour International Consortium (MaGIC) group European Urology Open Science 2019, 18: 9. DOI: 10.1016/s1569-9056(19)32477-7.
- α‐Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International ConsortiumO’Neill A, Xia C, Krailo MD, Shaikh F, Pashankar FD, Billmire DF, Olson TA, Amatruda JF, Villaluna D, Huang L, Malogolowkin M, Rodriguez‐Galindo C, Frazier AL. α‐Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium Cancer 2019, 125: 3649-3656. PMID: 31355926, DOI: 10.1002/cncr.32363.
- Sustained Remission After Maintenance Irinotecan in Patient With Multiply Relapsed HepatoblastomaNatarajan E, Auerbach C, Cheron R, Pashankar F. Sustained Remission After Maintenance Irinotecan in Patient With Multiply Relapsed Hepatoblastoma Journal Of Pediatric Hematology/Oncology 2019, 42: e659-e661. PMID: 31259823, DOI: 10.1097/mph.0000000000001544.
- Growing Teratoma Syndrome After Chemotherapy For Ovarian Immature TeratomaImran H, Siddiqui AH, Wilson F, Pashankar F. Growing Teratoma Syndrome After Chemotherapy For Ovarian Immature Teratoma Journal Of Pediatric Hematology/Oncology 2019, 42: e630-e633. PMID: 31205224, DOI: 10.1097/mph.0000000000001525.
- Outcomes of adolescent males with extracranial malignant germ cell tumors compared with children and young adults: A report from the Malignant Germ Cell Tumors International Consortium (MaGIC) group.Shaikh F, Stark D, Dang H, Xia C, Krailo M, Stenning S, Pashankar F, Rodriguez-Galindo C, Olson T, Hale J, Depani S, Stoneham S, Nicholson J, Murray M, Amatruda J, Billmire D, Fonseca A, Frazier A. Outcomes of adolescent males with extracranial malignant germ cell tumors compared with children and young adults: A report from the Malignant Germ Cell Tumors International Consortium (MaGIC) group. Journal Of Clinical Oncology 2019, 37: 10022-10022. DOI: 10.1200/jco.2019.37.15_suppl.10022.
- Alfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell international consortium.O'Neill A, Xia C, Krailo M, Shaikh F, Pashankar F, Billmire D, Olson T, Amatruda J, Villaluna D, Malogolowkin M, Rodriguez-Galindo C, Frazier A. Alfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell international consortium. Journal Of Clinical Oncology 2019, 37: 10036-10036. DOI: 10.1200/jco.2019.37.15_suppl.10036.
- Carcinomas in the children and young adults: A report form Children’s Oncology Group APEC14B1 study.Venkatramani R, Piao J, Krailo M, Rodriguez-Galindo C, Pashankar F. Carcinomas in the children and young adults: A report form Children’s Oncology Group APEC14B1 study. Journal Of Clinical Oncology 2019, 37: e21505-e21505. DOI: 10.1200/jco.2019.37.15_suppl.e21505.
- Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology GroupFonseca A, Xia C, Lorenzo AJ, Krailo M, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Billmire DF, Rodriguez-Galindo C, Frazier AL, Shaikh F. Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group Journal Of Clinical Oncology 2018, 37: 396-402. PMID: 30576269, PMCID: PMC6553816, DOI: 10.1200/jco.18.00790.
- Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumoursLawrence NJ, Chan H, Toner G, Stockler MR, Martin A, Yip S, Wong N, Yeung A, Mazhar D, Pashankar F, Frazier L, McDermott R, Walker R, Tan H, Davis ID, Grimison P, on behalf of ANZUP. Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours BMC Cancer 2018, 18: 854. PMID: 30157803, PMCID: PMC6114870, DOI: 10.1186/s12885-018-4745-3.
- Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?Shah R, Xia C, Krailo M, Amatruda JF, Arul SG, Billmire DF, Brady WE, Covens A, Gershenson DM, Hale JP, Hurteau J, Murray MJ, Nicholson JC, Olson TA, Pashankar F, Rodriguez-Galindo C, Shaikh F, Stark D, Frazier AL, Stoneham S. Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults? Gynecologic Oncology 2018, 150: 253-260. PMID: 29884437, DOI: 10.1016/j.ygyno.2018.05.025.
- Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International ConsortiumFrazier AL, Stoneham S, Rodriguez-Galindo C, Dang H, Xia C, Olson TA, Murray MJ, Amatruda JF, Shaikh F, Pashankar F, Billmire D, Krailo M, Stark D, Brougham MFH, Nicholson JC, Hale JP. Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium European Journal Of Cancer 2018, 98: 30-37. PMID: 29859339, DOI: 10.1016/j.ejca.2018.03.004.
- P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).Grimison P, Lawrence N, Stockler M, Martin A, Yip S, Wong N, Yeung A, Friedlander M, Mazhar D, Pashankar F, Quinn D, McDermott R, Walker R, Winstanley M, Hanning F, Weickhardt A, Stevanovic A, Davis I, Toner G. P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs). Journal Of Clinical Oncology 2018, 36: tps4596-tps4596. DOI: 10.1200/jco.2018.36.15_suppl.tps4596.
- Treatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: A report from the Children's Oncology Group AGCT0521 studyPashankar F, Frazier AL, Krailo M, Xia C, Pappo AS, Malogolowkin M, Olson TA, Rodriguez‐Galindo C. Treatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: A report from the Children's Oncology Group AGCT0521 study Pediatric Blood & Cancer 2018, 65: e27111. PMID: 29697191, PMCID: PMC6019185, DOI: 10.1002/pbc.27111.
- P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).Nayar N, Lawrence N, Stockler M, Martin A, Yip S, Wong N, Yeung A, Friedlander M, Mazhar D, Pashankar F, Quinn D, McDermott R, Walker R, Winstanley M, Hanning F, Weickhardt A, Stevanovic A, Davis I, Toner G, Grimison P. P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs). Journal Of Clinical Oncology 2018, 36: tps574-tps574. DOI: 10.1200/jco.2018.36.6_suppl.tps574.
- Ovarian Yolk Sac Tumors; Does Age Matter?Conter C, Xia C, Gershenson D, Hurteau J, Covens A, Pashankar F, Krailo M, Billmire D, Patte C, Fresneau B, Shaikh F, Stoneham S, Nicholson J, Murray M, Frazier AL. Ovarian Yolk Sac Tumors; Does Age Matter? International Journal Of Gynecological Cancer 2018, 28: 77-84. PMID: 29194189, DOI: 10.1097/igc.0000000000001149.
- Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 studyDicken BJ, Billmire DF, Krailo M, Xia C, Shaikh F, Cullen JW, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Rescorla FJ, Egler RA, Ross JH, Rodriguez‐Galindo C, Frazier AL. Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study Pediatric Blood & Cancer 2017, 65: e26913. PMID: 29286555, PMCID: PMC6219870, DOI: 10.1002/pbc.26913.
- Immature Ovarian TeratomaFaure-Conter C, Pashankar F. Immature Ovarian Teratoma Journal Of Pediatric Hematology/Oncology 2017, 39: 487-489. PMID: 28859031, DOI: 10.1097/mph.0000000000000950.
- P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).Grimison P, Lawrence N, Stockler M, Martin A, Yip S, Wong N, Yeung A, Friedlander M, Mazhar D, Pashankar F, Quinn D, Walker R, Winstanley M, Hanning F, Weickhardt A, Stevanovic A, Davis I, Toner G. P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs). Journal Of Clinical Oncology 2017, 35: tps4592-tps4592. DOI: 10.1200/jco.2017.35.15_suppl.tps4592.
- Germ Cell Tumors of the OvaryMatei D, Frazier A, Hurteau J, Pashankar F. Germ Cell Tumors of the Ovary 2017, 518-532. DOI: 10.1002/9781119196235.ch35.
- Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children’s Oncology GroupShaikh F, Cullen JW, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Villaluna D, Krailo M, Billmire DF, Rescorla FJ, Egler RA, Dicken BJ, Ross JH, Schlatter M, Rodriguez-Galindo C, Frazier AL. Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group Journal Of Clinical Oncology 2017, 35: jco.2016.67.654. PMID: 28240974, PMCID: PMC5455599, DOI: 10.1200/jco.2016.67.6544.
- Reduced and compressed cisplatin-based chemotherapy in children and adolescents with intermediate-risk extracranial malignant germ cell tumors: A report from the Children’s Oncology Group.Shaikh F, Cullen J, Olson T, Pashankar F, Malogolowkin M, Amatruda J, Villaluna D, Krailo M, Billmire D, Rescorla F, Egler R, Dicken B, Ross J, Schlatter M, Rodriguez-Galindo C, Frazier A. Reduced and compressed cisplatin-based chemotherapy in children and adolescents with intermediate-risk extracranial malignant germ cell tumors: A report from the Children’s Oncology Group. Journal Of Clinical Oncology 2016, 34: 10512-10512. DOI: 10.1200/jco.2016.34.15_suppl.10512.
- Treatment of childhood nasopharyngeal carcinoma (cNPC) with neoadjuvant chemotherapy (NAC) and concomitant chemoradiotherapy (CCRT): Results of the Children’s Oncology Group ARAR0331 study.Rodriguez-Galindo C, Krailo M, Krasin M, McCarville M, Hicks J, Pashankar F, Pappo A. Treatment of childhood nasopharyngeal carcinoma (cNPC) with neoadjuvant chemotherapy (NAC) and concomitant chemoradiotherapy (CCRT): Results of the Children’s Oncology Group ARAR0331 study. Journal Of Clinical Oncology 2016, 34: 10513-10513. DOI: 10.1200/jco.2016.34.15_suppl.10513.
- Treatment of childhood adrenocortical carcinoma (ACC) with surgery plus retroperitoneal lymph node dissection (RPLND) and multiagent chemotherapy: Results of the Children’s Oncology Group ARAR0332 protocol.Rodriguez-Galindo C, Pappo A, Krailo M, Pashankar F, Monteiro Caran E, Hicks J, McCarville M, Weldon C, Malkin D, Zambetti G, Filho A, LaQuaglia M, Mastellaro M, Ribeiro R. Treatment of childhood adrenocortical carcinoma (ACC) with surgery plus retroperitoneal lymph node dissection (RPLND) and multiagent chemotherapy: Results of the Children’s Oncology Group ARAR0332 protocol. Journal Of Clinical Oncology 2016, 34: 10515-10515. DOI: 10.1200/jco.2016.34.15_suppl.10515.
- Paediatric extracranial germ-cell tumoursShaikh F, Murray MJ, Amatruda JF, Coleman N, Nicholson JC, Hale JP, Pashankar F, Stoneham SJ, Poynter JN, Olson TA, Billmire DF, Stark D, Rodriguez-Galindo C, Frazier AL. Paediatric extracranial germ-cell tumours The Lancet Oncology 2016, 17: e149-e162. PMID: 27300675, DOI: 10.1016/s1470-2045(15)00545-8.
- Impact of red blood cell alloimmunization on sickle cell disease mortality: a case seriesNickel RS, Hendrickson JE, Fasano RM, Meyer EK, Winkler AM, Yee MM, Lane PA, Jones YA, Pashankar FD, New T, Josephson CD, Stowell SR. Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series Transfusion 2015, 56: 107-114. PMID: 26509333, DOI: 10.1111/trf.13379.
- Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International CollaborativePashankar F, Hale JP, Dang H, Krailo M, Brady WE, Rodriguez-Galindo C, Nicholson JC, Murray MJ, Bilmire DF, Stoneham S, Arul GS, Olson TA, Stark D, Shaikh F, Amatruda JF, Covens A, Gershenson DM, Frazier AL. Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative Cancer 2015, 122: 230-237. PMID: 26485622, PMCID: PMC5134834, DOI: 10.1002/cncr.29732.
- Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to CollaborationOlson TA, Murray MJ, Rodriguez-Galindo C, Nicholson JC, Billmire DF, Krailo MD, Dang HM, Amatruda JF, Thornton CM, Arul GS, Stoneham SJ, Pashankar F, Stark D, Shaikh F, Gershenson DM, Covens A, Hurteau J, Stenning SP, Feldman DR, Grimison PS, Huddart RA, Sweeney C, Powles T, Lopes LF, dos Santos Agular S, Chinnaswamy G, Khaleel S, Abouelnaga S, Hale JP, Frazier AL. Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration Journal Of Clinical Oncology 2015, 33: 3018-3028. PMID: 26304902, PMCID: PMC4979195, DOI: 10.1200/jco.2014.60.5337.
- Hydroxyurea Improves Oxygen Saturation in Children With Sickle Cell DiseasePashankar FD, Manwani D, Lee MT, Green NS. Hydroxyurea Improves Oxygen Saturation in Children With Sickle Cell Disease Journal Of Pediatric Hematology/Oncology 2015, 37: 242-243. PMID: 25222060, PMCID: PMC4362807, DOI: 10.1097/mph.0000000000000251.
- The Role of Registries and Tumor Banking in Rare Pediatric TumorsPashankar F, Bisogno G, Ribeiro R, Messinger Y, Schultz K, Rodriguez-Galindo C. The Role of Registries and Tumor Banking in Rare Pediatric Tumors Current Pediatrics Reports 2015, 3: 128-136. DOI: 10.1007/s40124-015-0077-9.
- Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United StatesFrazier AL, Hale JP, Rodriguez-Galindo C, Dang H, Olson T, Murray MJ, Amatruda JF, Thornton C, Arul GS, Billmire D, Shaikh F, Pashankar F, Stoneham S, Krailo M, Nicholson JC. Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United States Journal Of Clinical Oncology 2014, 33: 195-201. PMID: 25452439, PMCID: PMC4279239, DOI: 10.1200/jco.2014.58.3369.
- Rituximab for the Treatment of Acute Refractory ITPKim SG, Whyte D, Pashankar FD. Rituximab for the Treatment of Acute Refractory ITP Journal Of Pediatric Hematology/Oncology 2014, 36: e149-e151. PMID: 23669737, DOI: 10.1097/mph.0b013e318292f006.
- Surveillance After Initial Surgery for Pediatric and Adolescent Girls With Stage I Ovarian Germ Cell Tumors: Report From the Children's Oncology GroupBillmire DF, Cullen JW, Rescorla FJ, Davis M, Schlatter MG, Olson TA, Malogolowkin MH, Pashankar F, Villaluna D, Krailo M, Egler RA, Rodriguez-Galindo C, Frazier AL. Surveillance After Initial Surgery for Pediatric and Adolescent Girls With Stage I Ovarian Germ Cell Tumors: Report From the Children's Oncology Group Journal Of Clinical Oncology 2014, 32: 465-470. PMID: 24395845, PMCID: PMC4876316, DOI: 10.1200/jco.2013.51.1006.
- Weight Status of Children With Sickle Cell DiseaseChawla A, Sprinz PG, Welch J, Heeney M, Usmani N, Pashankar F, Kavanagh P. Weight Status of Children With Sickle Cell Disease Pediatrics 2013, 131: e1168-e1173. PMID: 23460681, DOI: 10.1542/peds.2012-2225.
- A 7-year-old boy with renal insufficiency and proteinuria after stem cell transplant for T-cell acute lymphoblastic leukemiaGoodwin JE, Palmer M, Pashankar F, Tufro A, Moeckel G. A 7-year-old boy with renal insufficiency and proteinuria after stem cell transplant for T-cell acute lymphoblastic leukemia Clinical Nephrology 2013, 82: 205-210. PMID: 23391318, PMCID: PMC6990651, DOI: 10.5414/cn107767.
- Candidate Sequence Variants and Fetal Hemoglobin in Children with Sickle Cell Disease Treated with HydroxyureaGreen NS, Ender KL, Pashankar F, Driscoll C, Giardina PJ, Mullen CA, Clark LN, Manwani D, Crotty J, Kisselev S, Neville KA, Hoppe C, Barral S. Candidate Sequence Variants and Fetal Hemoglobin in Children with Sickle Cell Disease Treated with Hydroxyurea PLOS ONE 2013, 8: e55709. PMID: 23409025, PMCID: PMC3567082, DOI: 10.1371/journal.pone.0055709.
- Massive splenic infarction in an adolescent with hemoglobin S‐HPFHWhyte D, Forget B, Chui DH, Luo H, Pashankar F. Massive splenic infarction in an adolescent with hemoglobin S‐HPFH Pediatric Blood & Cancer 2012, 60: e49-e51. PMID: 23281181, DOI: 10.1002/pbc.24444.
- Children's Oncology Group's 2013 blueprint for research: Rare tumorsRodriguez‐Galindo C, Krailo M, Frazier L, Chintagumpala M, Amatruda J, Katzenstein H, Malogolowkin M, Spector L, Pashankar F, Meyers R, Tomlinson G, Committee O. Children's Oncology Group's 2013 blueprint for research: Rare tumors Pediatric Blood & Cancer 2012, 60: 1016-1021. PMID: 23255219, PMCID: PMC4304764, DOI: 10.1002/pbc.24428.
- Parental and other factors associated with hydroxyurea use for pediatric sickle cell diseaseOyeku SO, Driscoll MC, Cohen HW, Trachtman R, Pashankar F, Mullen C, Giardina PJ, Velazco N, Racine AD, Green NS. Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease Pediatric Blood & Cancer 2012, 60: 653-658. PMID: 23129068, PMCID: PMC3625668, DOI: 10.1002/pbc.24381.
- Management of Thyroid Carcinoma in Children and Young AdultsRapkin L, Pashankar FD. Management of Thyroid Carcinoma in Children and Young Adults Journal Of Pediatric Hematology/Oncology 2012, 34: s39-s46. PMID: 22525405, DOI: 10.1097/mph.0b013e31824e37a6.
- Development of a Therapeutic Approach to Rare Cancers in ChildrenPashankar FD, Rodriguez-Galindo C, Pappo A. Development of a Therapeutic Approach to Rare Cancers in Children Journal Of Pediatric Hematology/Oncology 2012, 34: s37-s38. PMID: 22525404, DOI: 10.1097/mph.0b013e31824e378e.
- Management of Pancreatoblastoma in Children and Young AdultsGlick RD, Pashankar FD, Pappo A, LaQuaglia MP. Management of Pancreatoblastoma in Children and Young Adults Journal Of Pediatric Hematology/Oncology 2012, 34: s47-s50. PMID: 22525406, DOI: 10.1097/mph.0b013e31824e3839.
- Management of Ovarian and Testicular Sex Cord-stromal Tumors in Children and AdolescentsSchultz KA, Schneider DT, Pashankar F, Ross J, Frazier L. Management of Ovarian and Testicular Sex Cord-stromal Tumors in Children and Adolescents Journal Of Pediatric Hematology/Oncology 2012, 34: s55-s63. PMID: 22525408, DOI: 10.1097/mph.0b013e31824e3867.
- Phenotype diversity in type 1 Gaucher disease: discovering the genetic basis of Gaucher disease/hematologic malignancy phenotype by individual genome analysisLo SM, Choi M, Liu J, Jain D, Boot RG, Kallemeijn WW, Aerts JM, Pashankar F, Kupfer GM, Mane S, Lifton RP, Mistry PK. Phenotype diversity in type 1 Gaucher disease: discovering the genetic basis of Gaucher disease/hematologic malignancy phenotype by individual genome analysis Blood 2012, 119: 4731-4740. PMID: 22493294, PMCID: PMC3367875, DOI: 10.1182/blood-2011-10-386862.
- Effect of Hydroxyurea on Elevated Pulmonary Artery Pressures in Children with Sickle Cell DiseasePashankar F, Manwani D, Lee M, Green N. Effect of Hydroxyurea on Elevated Pulmonary Artery Pressures in Children with Sickle Cell Disease Blood 2011, 118: 4841-4841. DOI: 10.1182/blood.v118.21.4841.4841.
- The United StatesPashankar F, Rodriguez-Galindo C. The United States 2011, 113-115. DOI: 10.1007/978-3-642-04197-6_12.
- Acute Constipation in Children Receiving Chemotherapy for CancerPashankar FD, Season JH, McNamara J, Pashankar DS. Acute Constipation in Children Receiving Chemotherapy for Cancer Journal Of Pediatric Hematology/Oncology 2011, 33: e300-e303. PMID: 21941132, DOI: 10.1097/mph.0b013e31821a0795.
- Bi‐allelic deletions within 13q14 and transient trisomy 21 with absence of GATA1s in pediatric acute megakaryoblastic leukemiaMassaro SA, Bajaj R, Pashankar FD, Ornstein D, Gallagher PG, Krause DS, Li P. Bi‐allelic deletions within 13q14 and transient trisomy 21 with absence of GATA1s in pediatric acute megakaryoblastic leukemia Pediatric Blood & Cancer 2011, 57: 516-519. PMID: 21538823, PMCID: PMC4517576, DOI: 10.1002/pbc.23156.
- Understanding Provider Barriers to Hydroxyurea Use for Pediatric Sickle Cell DiseaseOyeku S, Green N, Pashankar F, Giardina P, Mullen C, Driscoll C. Understanding Provider Barriers to Hydroxyurea Use for Pediatric Sickle Cell Disease Blood 2010, 116: 255-255. DOI: 10.1182/blood.v116.21.255.255.
- Genetics of HbF and HbF Response to Hydroxyurea In Pediatric Sickle Cell Disease: A Multi-Site Pilot Analysis of Candidate SNP VariantsGreen N, Ender K, Pashankar F, Driscoll C, Giardina P, Mullen C, Clark L, Crotty J, Burney M, Hoppe C, Barral S. Genetics of HbF and HbF Response to Hydroxyurea In Pediatric Sickle Cell Disease: A Multi-Site Pilot Analysis of Candidate SNP Variants Blood 2010, 116: 2641-2641. DOI: 10.1182/blood.v116.21.2641.2641.
- T1155 Constipation in Children Receiving Chemotherapy for Cancer: Prevalence, Risk Factors and Severity of the ProblemSeason H, Pashankar F, Beardsley D, McNamara J, Pashankar D. T1155 Constipation in Children Receiving Chemotherapy for Cancer: Prevalence, Risk Factors and Severity of the Problem Gastroenterology 2009, 136: a-511. DOI: 10.1016/s0016-5085(09)62354-4.
- Sickle cell disease complicated by post‐streptococcal glomerulonephritis, cerebral hemorrhage and reversible posterior leucoencephalopathy syndromePashankar FD, Ment LR, Pearson HA. Sickle cell disease complicated by post‐streptococcal glomerulonephritis, cerebral hemorrhage and reversible posterior leucoencephalopathy syndrome Pediatric Blood & Cancer 2008, 50: 864-866. PMID: 17973321, DOI: 10.1002/pbc.21321.
- Intact T cell responses in ataxia telangiectasiaPashankar F, Singhal V, Akabogu I, Gatti RA, Goldman FD. Intact T cell responses in ataxia telangiectasia Clinical Immunology 2006, 120: 156-162. PMID: 16762595, DOI: 10.1016/j.clim.2006.04.568.
- MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use.Pashankar FD, O'Dorisio MS, Menda Y. MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use. Journal Of Nuclear Medicine 2005, 46 Suppl 1: 55s-61s. PMID: 15653652.
- Successful Chemotherapeutic Decompression of Primary Endodermal Sinus Tumor Presenting With Severe Spinal Cord CompressionPashankar F, Steinbok P, Blair G, Pritchard S. Successful Chemotherapeutic Decompression of Primary Endodermal Sinus Tumor Presenting With Severe Spinal Cord Compression Journal Of Pediatric Hematology/Oncology 2001, 23: 170-173. PMID: 11305721, DOI: 10.1097/00043426-200103000-00010.
- Analysis of the intracellular signalling domain of the human growth hormone receptor in children with idiopathic short statureJohnston L, Pashankar F, Camacho‐Hübner C, Savage M, Clark A. Analysis of the intracellular signalling domain of the human growth hormone receptor in children with idiopathic short stature Clinical Endocrinology 2000, 52: 463-469. PMID: 10762289, DOI: 10.1046/j.1365-2265.2000.00940.x.